Detail of the clinical trial
| Title of the trial | A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma |
|---|---|
| EudraCT number | 2015-005053-12 |
| Protocol number | MK3475-204 |
| Sponsor | Merck Sharp & Dohme LLC, 126 East Lincoln Ave.,P.O.BOX 2000,Rahway, New Jersey 07065, United States of America |
| Indications | Hemato-oncology |
| Diagnosis | Hodgkin Lymphoma |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2017 |
| Date of approval by Institute (SÚKL) | 30.6.2017 |
| Date of approval by EC | 1.6.2017 |
| Date of initiation CT in ČR | 1.11.2017 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
FN Brno,Interní hematologická a onkologická klinika ,Jihlavská 20,Brno,625 00 Všeobecná fakultní nemocnice v Praze,I. interní klinika - klinika hematologie VFN a 1. LF UK,U nemocnice 2,Praha 2,128 08 (discontinued) FN Hradec Králové,IV. interní hematologická klinika LF UK,Sokolská 581,Hradec Králové - Nový Hradec Králové,500 05 FN Královské Vinohrady,Interní hematologická klinika,Šrobárova 1150/50,Praha 10,100 34 Fakultní nemocnice Ostrava,Klinika hematoonkologie,17. listopadu 1790,Ostrava,708 52 (discontinued) |
cz